Skip to content

Gedeon Richter: Cariprazine could become best-selling atypical antipsychotic drug

  • News

Cariprazine, an original antipsychotic drug developed by Hungarian pharmaceutical company Gedeon Richter Plc. is available in 64 countries and has become a multiple blockbuster in the US, with sales of nearly $3 billion. It is a unique achievement that a Hungarian drug candidate – discovered and developed locally – has been granted FDA and EU approvals, and the company already has several further molecules in its pipeline. "Thousands of psychiatrists arrived to Budapest for the European Congress of Psychiatry, and perhaps even they are unaware of how important role Hungarian researchers have played in this field worldwide. We have nearly 1200 researchers, making us the largest innovation base in the whole region. The fact that cariprazine has been among the TOP 100 drugs by sales for several years now is an outstanding achievement comparable to winning an Olympic medal," Gábor Orbán, CEO of Richter said… 

more »Gedeon Richter: Cariprazine could become best-selling atypical antipsychotic drug

MEDSIR: Two Translational Studies Focused on Biomarkers at AACR 2024

  • News

MEDSIR, a leading company dedicated to the strategic design of independent clinical research, participated in the Annual Meeting of the American Association for Cancer Research, a premier event that brings together scientists, clinicians, industry professionals, advocates, and other stakeholders in the field of cancer research, presenting the results of two sub-studies focused on biomarkers: transFal, focused on patients with HR+/HER2- advanced breast cancer and METSGain, centered on patients with early breast cancer. Both studies underscore the importance of utilizing biomarkers. Their early detection has been shown to increase patient survival rates by aiding in selecting the most appropriate treatment for patients. In the context of personalized medicine, biomarkers are also important for tailoring treatments for individual patients based on their unique biological characteristics, allowing for more precise and effective medical interventions. These findings represent significant strides in understanding and leveraging… 

more »MEDSIR: Two Translational Studies Focused on Biomarkers at AACR 2024

Mortality figures in March significantly below previous years' levels

The number of deaths in Germany in March 2024 was significantly lower than in previous years. In total, 83,263 people died, according to a projection published on Tuesday by the Federal Statistical Office (Destatis), which is eight percent less than the average for the years 2020 to 2023. In February 2024, the number of deaths was still above the average for previous years […] Mortality figures in March significantly below previous years' levels

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired resistance to PD-1/L1 blockade – Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

FOSTER CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) — Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 5178). Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

FDA Roundup: April 9, 2024

Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: U.S. Food and Drug Administration 09 Apr, 2024, 15:31 ET On Friday, the FDA authorized for marketing MMI North America, Inc.’s Symani Surgical System, indicated for use during certain microsurgical procedures on small blood vessels and lymphatic ducts in adults. The system includes the use of a motion scaling function, which scales down the surgeon’s movements. Microsurgery covers procedures involving the use of microscopes and small instruments to perform small-scale surgical techniques. The system is intended for use by trained physicians in the operating environments described in the device’s labeling. On Friday, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and… 

more »FDA Roundup: April 9, 2024
Foto: Pexels.com

AI can predict pressure ulcer risk in hospital patients 

The new AI risk assessment model published today in BMJ Open increases prediction accuracy to more than 74% – an increase of more than 20% over existing methods. Common practices and guidelines for preventing pressure ulcers are time-consuming and burdensome for bedside nursing staff. The industry-standard tool for predicting pressure ulcer risk, the paper-based Braden Scale, has not changed since its introduction in the 1980s and has an accuracy rate of 54%, researchers note. The prediction algorithm developed by the team offers improved cost-effectiveness and significant savings. Since a risk assessment can take between five and 15 minutes per patient, this can mean up to 250 work hours per day and between 30,000 and 90,000 work hours per year in a single 500-bed facility. Using machine learning methods, researchers have analyzed the electronic health records of…

more »AI can predict pressure ulcer risk in hospital patients 

Crisis due to decline in European generics

  • News

A recently published study shows that Europe is facing a crisis due to a significant decline in the availability of generic drugs. Teva Pharmaceuticals, the world's largest manufacturer of generic drugs, claims in its study that the number of generics withdrawn from the market has increased by 12%, while the introduction of new generics has decreased by an average of 3% per year. In 2012, there were 40,280 different generics in Europe. However, just over a decade later, this number has fallen to only 29,836 generics, a considerable decrease of 26%. The Teva study, "The Critical Medicines Health Check," warns of escalating health challenges across Europe, pointing to antimicrobial resistance – adding that there are 31% fewer antibiotic medicines in the region today than there were ten years ago, with the number of...

more »Crisis due to decline in European generics

mRNA drug to lower blood lipids

According to a placebo-controlled, double-blind study led by researchers at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, an experimental treatment may further lower blood triglycerides. The findings were presented at the American College of Cardiology 2024 Scientific Session & Expo and simultaneously published in the New England Journal of Medicine. In the study, 154 adults receiving lipid-lowering therapy with moderate-to-severe hypertriglyceridemia were randomized to receive either 50 mg of Olezarsen, 80 mg of Olezarsen, or placebo. Olezarsen is an antisense oligonucleotide that inhibits APOC3, a gene linked to higher triglyceride levels by targeting its mRNA. The subcutaneous drug was administered every four weeks for one year. Compared to placebo, Olezarsen lowered triglyceride levels by 49% at the 50-mg dose and by...

more »mRNA drug to lower blood lipids

Clarius and ThinkSono Introduce a New AI-Guided Ultrasound System Enabling Rapid Assessments of DVTs

Clarius Mobile Health, a leading provider of high-definition handheld ultrasound systems, and ThinkSono, a pioneering medical technology company specializing in ultrasound artificial intelligence (AI) guidance solutions, are introducing a new AI-guided ultrasound system in Europe, which will improve the efficiency of detecting deep vein thrombosis (DVT). ThinkSono Guidance, an AI App that pairs with Clarius ultrasound scanners, recently attained Class llb CE mark regulatory approval. DVT is a blood clot found commonly in the leg and is a leading cause of preventable hospital death in Europe and the United States. Patients often wait for hours or days for test results performed by ultrasound-trained clinicians.